Becton Dickinson and Co (BDX) to Issue Quarterly Dividend of $0.75
Becton Dickinson and Co (NYSE:BDX) declared a quarterly dividend on Monday, January 22nd, RTT News reports. Shareholders of record on Friday, March 9th will be given a dividend of 0.75 per share by the medical instruments supplier on Friday, March 30th. This represents a $3.00 dividend on an annualized basis and a yield of 1.27%.
Becton Dickinson and has raised its dividend payment by an average of 9.6% annually over the last three years and has raised its dividend annually for the last 46 consecutive years. Becton Dickinson and has a dividend payout ratio of 28.1% indicating that its dividend is sufficiently covered by earnings. Analysts expect Becton Dickinson and to earn $12.61 per share next year, which means the company should continue to be able to cover its $3.00 annual dividend with an expected future payout ratio of 23.8%.
Becton Dickinson and (BDX) traded up $2.20 during trading on Monday, reaching $236.71. 1,324,309 shares of the company’s stock were exchanged, compared to its average volume of 1,594,943. The company has a current ratio of 5.58, a quick ratio of 5.03 and a debt-to-equity ratio of 1.44. Becton Dickinson and has a 52 week low of $169.19 and a 52 week high of $236.74. The firm has a market cap of $54,300.00, a P/E ratio of 50.91, a PEG ratio of 1.79 and a beta of 1.07.
A number of research firms have issued reports on BDX. Bank of America restated a “buy” rating and set a $260.00 target price on shares of Becton Dickinson and in a research report on Friday. Zacks Investment Research upgraded shares of Becton Dickinson and from a “hold” rating to a “buy” rating and set a $259.00 price target on the stock in a research report on Friday. Stifel Nicolaus reiterated a “buy” rating and issued a $245.00 price target on shares of Becton Dickinson and in a research report on Friday, November 3rd. Royal Bank of Canada reiterated a “sector perform” rating and issued a $230.00 price target (up from $210.00) on shares of Becton Dickinson and in a research report on Friday, November 3rd. Finally, Morgan Stanley increased their price target on shares of Becton Dickinson and from $205.00 to $245.00 and gave the company an “equal weight” rating in a research report on Friday, November 3rd. Four equities research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $233.80.
About Becton Dickinson and
Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.